Yahoo
Tokyo - Delayed Quote JPY

Tsumura & Co. (4540.T)

3,821.00 +47.00 (+1.25%)
At close: October 30 at 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 4540.T
  • Previous Close 3,774.00
  • Open 3,770.00
  • Bid 3,818.00 x --
  • Ask 3,823.00 x --
  • Day's Range 3,770.00 - 3,839.00
  • 52 Week Range 3,513.00 - 4,403.00
  • Volume 402,800
  • Avg. Volume 489,351
  • Market Cap (intraday) 284.838B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 9.48
  • EPS (TTM) 402.92
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield 158.00 (4.14%)
  • Ex-Dividend Date Mar 30, 2027
  • 1y Target Est 4,314.00

Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal/throat inflammation symptoms. It is also involved in manufacturing and sales of prescription drugs and over-the-counter Kampo medicines. In addition, it produces and sells alcoholic beverages and food products. Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.

www.tsumura.co.jp

4,923

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4540.T
2.33%
Nikkei 225 (^N225)
25.73%

1-Year Return

4540.T
12.49%
Nikkei 225 (^N225)
23.31%

3-Year Return

4540.T
61.32%
Nikkei 225 (^N225)
106.18%

5-Year Return

4540.T
25.15%
Nikkei 225 (^N225)
119.05%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 49.7B
Earnings 6.46B
Profit Margin 12.99%

Q1

FY26

Q2

FY26

Q3

FY26

Q1

FY27

0
10B
20B
30B
40B
50B
12.0%
14.0%
16.0%
18.0%

Analyst Insights

View More

Analyst Price Targets

3,700.00
4,314.00 Average
3,821.00 Current
5,770.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.16%

  • Return on Assets (ttm)

    4.14%

  • Return on Equity (ttm)

    9.32%

  • Revenue (ttm)

    199.22B

  • Net Income Avi to Common (ttm)

    30.21B

  • Diluted EPS (ttm)

    402.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    77.28B

  • Total Debt/Equity (mrq)

    39.09%

  • Levered Free Cash Flow (ttm)

    -52.48B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: